Fusion Antibodies PLC Ordinary Shares FAB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBX11.50
- Day Range
- GBX11.00–11.49
- 52-Week Range
- GBX9.00–20.00
- Bid/Ask
- GBX0.00 / GBX0.00
- Shares Outstanding
- 125.16M
- Market Cap
- GBX1.41B
- Volume/Avg
- 404,009 / 353,862
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.15
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Fusion Antibodies PLC is a Contract Research Organisation (CRO) providing antibody identification, engineering, and expression services for the discovery and development of antibodies for human and veterinary therapeutics, as well as for diagnostics. Its customers are pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company’s three core service areas include: Discovery (identification, screening, and sequencing of novel antibodies); Engineering (optimising the performance of antibodies); and Supply (production and purification of antibodies for further development). Geographically company generates the majority of its revenue from North America and the Rest of the World, followed by the United Kingdom and the Rest of Europe.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 21
- Website
- https://www.fusionantibodies.com
Valuation
|
Metric
|
FAB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 8.67 |
Price/Sales | 6.15 |
Price/Cash Flow | — |
Price/Earnings
FAB
Financial Strength
|
Metric
|
FAB
|
|---|---|
Quick Ratio | 2.39 |
Current Ratio | 2.82 |
Interest Coverage | −56.65 |
Quick Ratio
FAB
Profitability
|
Metric
|
FAB
|
|---|---|
Return on Assets (Normalized) | −57.70% |
Return on Equity (Normalized) | −110.57% |
Return on Invested Capital (Normalized) | −88.06% |
Return on Assets
FAB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#^Bflg | LOCK|@?@L> | $128B | |||
| Moderna Inc
MRNA
| LOCK|$<f$rnM | LOCK|B#s | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|&^$KWl# | LOCK|!c!b | $76B | |||
| argenx SE ADR
ARGX
| LOCK|#S#FmQ | LOCK|<@z | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#mQ&zf | LOCK|Py | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>#H&$? | LOCK|w%#^G | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|%Qgn^jR% | LOCK|@yG^ | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|g>v&m$ | LOCK|P#b | $24B | |||
| Incyte Corp
INCY
| LOCK|y?mKh$ | LOCK|Z$g | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|s#q!GH | LOCK|Vg | $15B |
United States